Corporate News

Block Listing Six Monthly Return

27 January 2023

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant: Polarean Imaging Plc
Name of scheme: Polarean Share Option Plan
Number and class of securities originally admitted: 8,000,000 ordinary shares of £0.00037 each
Date of admission: 29 July 2021
Period of return: From: 28 July 2022 To: 26 January 2023
Balance of unallotted securities under scheme(s) from previous return: 4,025,657
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 4,025,657
Total number of securities in issue at the end of the period 213,047,509


Name of contact: Richard Hullihen, Chief Executive Officer
Telephone number of contact: + 44 (0)20 7933 8780 or  [email protected]



Polarean Imaging plc /
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Kenneth West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)+44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)  
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or [email protected]
Anna Dunphy /Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082


About Polarean (

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space.  Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung function, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform, Polarean’s vision is to help address the global unmet medical needs of patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On December 23, 2022, the FDA granted approval for Polarean’s first drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarized). 129Xe MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

XENOVIEWTM is a trademark of Polarean, Inc.                                                                   POL-PR-2201

Investor Alert

Sign up for Email Alerts